Drug
Influenza A Virus Monovalent Vaccine
Influenza A Virus Monovalent Vaccine: highest development phase Phase 2, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted NCT01416571 | Phase 2 | Influenza |
Latest
No recent events.
Follow Influenza A Virus Monovalent Vaccine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.